Drug Resistance in Hematological Malignancies

Patrick Auberger; Jerome Tamburini-Bonnefoy; Alexandre Puissant

doi:10.3390/ijms21176091

Drug Resistance in Hematological Malignancies

Int J Mol Sci. 2020 Aug 24;21(17):6091. doi: 10.3390/ijms21176091.

Authors

Patrick Auberger¹, Jerome Tamburini-Bonnefoy², Alexandre Puissant³

Affiliations

¹ Team "Myeloid Malignancies and Multiple Myeloma", Université Cote d'Azur, Inserm U1065/C3M, 06204 Nice, France.
² Cochin Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France.
³ INSERM U944, Hôpital St Louis, 75010 Paris, France.

Abstract

Hematological malignancies define a highly heterogeneous set of blood-, bone marrow-, and organ-associated diseases with highly variable prognoses that constantly relapse upon treatment [...].

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Combined Modality Therapy
Drug Resistance, Neoplasm* / drug effects
Drug Therapy, Combination
Hematologic Neoplasms / drug therapy*
Hematologic Neoplasms / therapy
Humans
Immunotherapy / methods
Immunotherapy, Adoptive / methods
Immunotherapy, Adoptive / trends
Molecular Targeted Therapy / trends